XBiotech Inc. (XBIT)
| Market Cap | 513.02M |
| Revenue (ttm) | 36.17M |
| Net Income (ttm) | -13.78M |
| Shares Out | 29.42M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $17.11 |
| Previous Close | $17.12 |
| Change ($) | -0.01 |
| Change (%) | -0.06% |
| Day's Open | 17.12 |
| Day's Range | 16.96 - 17.39 |
| Day's Volume | 32,571 |
| 52-Week Range | 12.76 - 21.48 |
The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Phas...
XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer
With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectious Strain R...
Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Alb...
XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safer/more effective therapeutics through human-based monoclonal antibodies. XBiotech's pipeline consists of 4 candidate...
Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential
As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Cataly...
With the Arrival of Flu Season, Development of a Breakthrough Therapeutic for Treating Influenza and COVID-19 Co-Infections is Urgently Needed With the Arrival of Flu Season, Development of a Breakthrou...
FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients
XBiotech Inc. (NASDAQ: XBIT) shares made a handy gain on Monday after the company said that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2.
The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood
Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.
XBiotech: Well Funded, Working On The Next Bermekimab, And Undervalued
After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021 After Sale of its Previous Anti-IL-1a True H...
Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy Antibody Therapy Targeting Interleukin-1a significa...
Donors with Potent Natural Immunity Against the Virus are Identified as the Starting Point for XBiotech’s Drug Development Program to Treat COVID-19
These are the small cap stocks with the best value, fastest growth, and most momentum for May.
New antibody to block IL-1⍺ scheduled to enter clinical trials as next generation anti-inflammatory therapy in 2021 New antibody to block IL-1⍺ scheduled to enter clinical trials as next generation anti...
AUSTIN, Texas, April 03, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration (FDA) inve...
AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., N...
AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor. The corrected pr...
The company's offer to buy back shares was overtendered, resulting in a prorated deal.
AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p...
XBiotech Is Trading Below Its $30 Offer Price For Good Reason, But It Still Could Rise
The company is offering to buy back shares from investors at a big premium.
AUSTIN, Texas, Jan. 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of i...
Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Anti...
XBiotech Move To Out-Licence Next Generation Antibody Brings In Substantial Cash For Pipeline Expansion
AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to...
XBiotech announced a massive deal with Johnson & Johnson subsidiary Janssen, which is thrusting the overlooked biopharma onto the radars of investors.
Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some.
XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen XBiotech wi...
Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS
AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL...
AUSTIN, Texas, Oct. 23, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical s...
Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a Devastating Disease with Currently No Approved Therapies Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a Devastati...
Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Saturday, October 12, 2019 Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Saturday, Octob...
AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the u...
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
About XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical tri... [Read more...]
| Industry Biotechnology | IPO Date Apr 15, 2015 |
| CEO John Simard | Employees 91 |
| Stock Exchange NASDAQ | Ticker Symbol XBIT |
Analyst Forecasts
The average 12-month stock price forecast for XBiotech is 18.00, which is an increase of 5.20% from the latest price.